We will present the case of a patient with nonischemic cardiomyopathy who underwent heart transplantation from a genetically modified pig source animal and whose course was notable for detection of porcine CMV by plasma microbial cell-free DNA and xenograft failure.
Describe infectious disease risk assessment and mitigation in potential xenograft donors
Describe the selection of immunosuppressive regimens and prophylactic antimicrobials for human xenograft recipients
Understand strategies to screen for and treat potential xenograft-related infections
Organized in collaboration with the TID Official Journal
Associate Professor of Medicine
Associate Director, Transplant Infectious Diseases
Emory University School of Medicine
Stephanie Pouch, MD, MS, FAST is an Associate Professor of Medicine and transplant infectious diseases physician at Emory University School of Medicine. Her clinical and research interests include multidrug-resistant bacterial infections in transplant recipients, as well as donor evaluation and donor-derived infections. She is active within the transplant community, serving as a Councilor in the TID Section of TTS, Co-Chair of the American Society of Transplantation Infectious Disease Community of Practice’s Donor Evaluation Working Group, and Vice Chair of the Organ Procurement and Transplantation Network Disease Transmission Advisory Committee.
Associate Professor Medicine
Institute of Human Virology
Dept of Medicine, Division of Infectious Diseases
University of Maryland School of Medicine
Kapil Saharia, MD, MPH is an Associate Professor of Medicine at University of Maryland School of Medicine and Section Chief of Solid Organ Transplant Infectious Diseases at University of Maryland Medical Center. He is the current Chair of the AST Infectious Diseases Community of Practice Safety/QI Working Group. His research interests include infectious disease outcomes research in solid organ transplant recipients and evaluation of novel diagnostic assays to improve the infectious disease management of solid organ transplant recipients.
Professor of Medicine, Harvard Medical School
Transplant Infectious Disease and Compromised Host Program Associate Director Transplant Center Massachusetts General Hospital
Jay A. Fishman, M.D. is Professor of Medicine at Harvard Medical School, Director of the Transplant Infectious Diseases and Compromised Host Program at the Massachusetts General Hospital (MGH), and Associate Director of the MGH Transplant Center. Dr. Fishman completed Internal Medicine and Infectious Disease training at MGH, and Fellowships in Molecular Biology and Genetics at Harvard Medical School. The Transplant Infectious Disease and Immunocompromised Host Program provides lifelong care for solid organ and stem cell transplant recipients and other immunocompromised hosts. With his background in immunology, virology and molecular biology, Dr. Fishman has defined the infectious risks in xenotransplantation, notably the role of porcine endogenous retrovirus and cytomegalovirus. He has over 300 peer-reviewed publications. He is Past-President of the American Society of Transplantation and Councilor of the International Xenotransplantation Association, Fellow of the American College of Physicians, American Society of Transplantation, and Infectious Disease Society of America.
Associate Professor of Surgery
University of Alabama at Birmingham
Dr. Porrett is the Director for Clinical & Translational Research
or the UAB Comprehensive Transplant Institute. She is also the
inaugural director for vascularized composite allotransplantation
(VGA) for the UAB CTI . Dr. Porrett has diverse intellectual
interests and expertise. Her NIH-funded immunology laboratory
studies maternal immune cell fate and function during pregnancy
in both human and animal models. Recently, Dr. Porrett
expanded her portfolio to include xenotransplantation and has
published the world's first experience of a clinical-grade, geneedited
porcine kidney transplant into a human being.